Finally, we sought to investigate if NLRC5 overexpression in an ICV could increase antitumoral protection, given that mice bearing NLRC5+ tumors generated T cells with greater activation and recognition of autologous TAAs and that the infection triggered by an oncolytic virus would render the cellular vaccine more immunogenic (Figure 6G). The gene discussed is NLRC5; the disease is infection.